# SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

> **NCT00215540** · PHASE2 · TERMINATED · sponsor: **Windtree Therapeutics** · enrollment: 136 (actual)

## Conditions studied

- Respiratory Distress Syndrome, Newborn
- Premature Birth
- Bronchopulmonary Dysplasia

## Interventions

- **DRUG:** Lucinactant 175 mg/kg
- **DRUG:** Lucinactant 90 mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00215540
- **Lead sponsor:** Windtree Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-02
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 136 (ACTUAL)
- **Why stopped:** Concerns related to availability of drug product
- **Last updated:** 2012-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00215540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00215540, "SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00215540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*